TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.

  title={TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.},
  author={Joseph Keane},
  volume={44 6},
Newer TNF blockers (etanercept, infliximab and adalimumab) have contributed greatly to the control of chronic inflammatory disease. Many of the damaging inflammatory mechanisms that they inhibit are, however, important in maintaining tuberculosis in the latent phase (latent tuberculosis infection or LTBI). There is considerable evidence that links reactivation of LTBI to the use of anti-TNF monoclonal antibody (mAb) treatments, which appear to result in disruption of the granuloma that normally… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 111 extracted citations


Publications referenced by this paper.
Showing 1-10 of 56 references

Update on the British Society for Rheumatology guidelines for prescribing TNF blockers in adults with rheumatoid arthritis

  • J Ledinghan, C. Deighton
  • (update of previous guidelines of April
  • 2001
Highly Influential
6 Excerpts

Impact of screening for latent TB prior to initiating anti-TNF therapy

  • J Perez, H Kupper, A Radin, G. Spencer-Green
  • San Antonio (TX)(Abstract): American College of…
  • 2005
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…